Moving towards patient-centered medicine for COPD management: Multidimensional approaches versus phenotype-based medicine-a critical view

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 5, 2014, Pages 591-602

  Lopez Campos, Jose Luis ^a,b   Bustamante, Víctor ^c   Muñoz, Xavier ^b,d   Barreiro, Esther ^b,e  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

clinical phenotypes; COPD; guidelines; independent variables; multidimensional scores

Indexed keywords

ADAPTATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; MEDICAL PRACTICE; PATIENT CARE; PHENOTYPE; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; DISEASE MANAGEMENT; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TRENDS;

DISEASE MANAGEMENT; FORCED EXPIRATORY VOLUME; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT-CENTERED CARE; PHENOTYPE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84907050228     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.898035     Document Type: Review

References (70)

1. Fletcher C, Peto R. The natural history of chronic airfl ow obstruction. Br Med J 1977; 1(6077):1645-1648.
2. Soriano JB, Calle M, Montemayor T, Alvarez-Sala JL, Ruiz-Manzano J, Miravitlles M. The general public's knowledge of chronic obstructive pulmonary disease and its determinants: current situation and recent changes. Arch Bronconeumol 2012; 48(9):308-315.
3. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Macnee W, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365(13):1184-1192.
4. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, Macnee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122.
5. Espinosa de los Monteros MJ, Pena C, Soto Hurtado EJ, Jareno J, Miravitlles M. Variability of respiratory symptoms in severe COPD. Arch Bronconeumol 2012; 48(1):3-7.
6. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37(2):264-272.
7. Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis 2013; 8:231-238.
8. Lopez Varela MV, Montes de OM. Variability in COPD: the PLATINO study viewpoint. Arch Bronconeumol 2012; 48(4):105-106.
9. Decramer M, Janssens W. Chronic obstructive pumonary disease and comorbidities. Lancet Respir Med 2013; 1(1):73-83.
10. Llauger Rosello MA, Pou MA, Dominguez L, Freixas M, Valverde P, Valero C. [Treating COPD in chronic patients in a primary-care setting]. Arch Bronconeumol 2011; 47(11):561-570.
11. Lopez-Campos JL, Soriano JB. A comprehensive, national survey of spirometry in Spain: current bottlenecks and future directions in primary and secondary care. Chest 2013 Aug; 144(2):601-609.
12. Miravitlles M. Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch Bronconeumol 2011; 47(6):271-273.
13. Rodriguez-Roisin R. Arguments against inhaled glucocorticoids in COPD by phenotype instead of by severity. Arch Bronconeumol 2011; 47(6):269-270.
14. Izquierdo Alonso JL, De Lucas RP, Rodriguez Glez-Moro JM. The use of the lower limit of normal as a criterion for COPD excludes patients with increased morbidity and high consumption of health-care resources. Arch Bronconeumol 2012; 48(7):223-228.
15. Monteagudo M, Rodriguez-Blanco T, Parcet J, Penalver N, Rubio C, Ferrer M, Miravitlles M. Variability in the performing of spirometry and its consequences in the treatment of COPD in primary care. Arch Bronconeumol 2011; 47(5):226-233.
16. Barreiro E, Sieck G. Muscle dysfunction in COPD. J Appl Physiol 2013; 114(9):1220-1221.
17. Barreiro E, Sznajder JI. Epigenetic regulation of muscle phenotype and adaptation: a potential role in COPD muscle dysfunction. J Appl Physiol 2013; 114(9):1263-1272.
18. Gea J, Agusti A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol 2013; 114(9):1222-1234.
19. Natanek SA, Riddoch-Contreras J, Marsh GS, Hopkinson NS, Man WD, Moxham J, Polkey MI, Kemp PR. Yin Yang 1 expression and localisation in quadriceps muscle in COPD. Arch Bronconeumol 2011; 47(6):296-302.
20. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, Gosker HR, Schols AM, Moxham J, Polkey MI, Wouters EF. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010; 36(1):81-88.
21. Agusti A, Macnee W. The COPD control panel: towards personalised medicine in COPD. Th orax 2013; 68(7):687-690.
22. Lopez-Campos JL, Peces-Barba G, Soler-Cataluna JJ, Soriano JB, De Lucas RP, de-Torres JP, Marin JM, Casanova C. Chronic obstructive pulmonary disease history assessment in Spain: a multidimensional chronic obstructive pulmonary disease evaluation. Study methods and organization. Arch Bronconeumol 2012; 48(12):453-459.
23. Lopez-Campos JL. [Treatment strategies in chronic obstructive pulmonary disease: a proposal for standardization]. Arch Bronconeumol 2010; 46(12):617-620.
24. Rodriguez-Roisin R, Agusti A. The GOLD initiative 2011: a change of paradigm Arch Bronconeumol 2012; 48(8):286-289.
25. Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)-why and what Clin Respir J 2012; 6(4):208-214.
26. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347-365.
27. Lin FJ, Lee TA, Wong PS, Pickard AS. Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. J Eval Clin Pract 2013 Oct; 19(5):953-960.
28. Sillen MJ, Franssen FM, Delbressine JM, Uszko-Lencer NH, Vanfleteren LE, Rutten EP, Wouters EF, Spruit MA. Heterogeneity in clinical characteristics and co-morbidities in dyspneic individuals with COPD GOLD D: Findings of the DICES trial. Respir Med 2013; 107(8):1186-1194.
29. Gruffydd-Jones K. GOLD guidelines 2011: what are the implications for primary care Prim Care Respir J 2012; 21(4):437-441.
30. Idrovo AJ. Three criteria for ecological fallacy. Environ Health Perspect 2011; 119(8):A332.
31. Han MK, Muellerova H, Curran-Everet D, Dransfield MT, Washko GR, Regan EA, Bowler RP, Beaty TH, Hokanson JE, Lynch DA. GOLD 2011 disease severity classifi cation in COPDGene: a prospective cohort study. Lancet Respir Med 2013; 1(1):43-50
32. Jones P, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in a primary care COPD population: implications for the new GOLD 2011 classifi cation. Eur Respir J 2012 Sep; 42(3):647-654.
33. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, Macnee W, Silverman EK, Tal-Singer R. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008; 31(4):869-873.
34. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363(12):1128-1138.
35. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classifi cation: a study of the general population. Am J Respir Crit Care Med 2012; 186(10):975-981.
36. Marin JM, Alfageme I, Almagro P, Casanova C, Esteban C, Soler-Cataluna JJ, de Torres JP, Martinez-Camblor P, Miravitlles M, Celli BR, Soriano JB. Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J 2013; 42(2):323-332.
37. Soriano JB, Alfageme I, Almagro P, Casanova C, Esteban C, Soler-Cataluna JJ, de Torres JP, Martinez-Camblor P, Miravitlles M, Celli BR, Marin JM. Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classifi cation. Chest 2013; 143(3):694-702.
38. Celli BR, Cote CG, Marin JM, Casanova C, Montes de OM, Mendez RA, Pinto P, V, Cabral HJ. The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10):1005-1012.
39. Ko FW, Tam W, Tung AH, Ngai J, Ng SS, Lai K, Au KF, Hui DS. A longitudinal study of serial BODE indices in predicting mortality and readmissions for COPD. Respir Med 2011; 105(2):266-273.
40. Martinez FJ, Han MK, Andrei AC, Wise R, Murray S, Curtis JL, Sternberg A, Criner G, Gay SE, Reilly J, Make B, Ries AL, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 2008; 178(5):491-499.
41. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131(3):696-704.
42. Marin JM, Carrizo SJ, Casanova C, Martinez-Camblor P, Soriano JB, Agusti AG, Celli BR. Prediction of risk of COPD exacerbations by the BODE index. Respir Med 2009 Mar;103(3):373-8.
43. Cardoso F, Tufanin AT, Colucci M, Nascimento O, Jardim JR. Replacement of the 6-min walk test with maximal oxygen consumption in the BODE Index applied to patients with COPD: an equivalency study. Chest 2007; 132(2):477-482.
44. Cote CG, Pinto-Plata VM, Marin JM, Nekach H, Dordelly LJ, Celli BR. The modifi ed BODE index: validation with mortality in COPD. Eur Respir J 2008; 32(5):1269-1274.
45. Lopez-Campos JL, Cejudo P, Marquez E, Ortega F, Quintana E, Carmona C, Barrot E. Modifi ed BODE indexes: Agreement between multidimensional prognostic systems based on oxygen uptake. Int J Chron Obstruct Pulmon Dis 2010; 5:133-140.
46. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez LS, Tordera MP, Sanchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103(5):692-699.
47. Williams JE, Green RH, Warrington V, Steiner MC, Morgan MD, Singh SJ. Development of the i-BODE: validation of the incremental shuttle walking test within the BODE index. Respir Med 2012; 106(3):390-396.
48. Puhan MA, Garcia-Aymerich J, Frey M, ter RG, Anto JM, Agusti AG, Gomez FP, Rodriguez-Roisin R, Moons KG, Kessels AG, Held U. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374(9691):704-711.
49. Azarisman MS, Fauzi MA, Faizal MP, Azami Z, Roslina AM, Roslan H. The SAFE (SGRQ score, air-fl ow limitation and exercise tolerance) Index: a new composite score for the stratifi cation of severity in chronic obstructive pulmonary disease. Postgrad Med J 2007; 83(981):492-497.
50. Briggs A, Spencer M, Wang H, Mannino D, Sin DD. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med 2008; 168(1):71-79.
51. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180(12):1189-1195.
52. Esteban C, Quintana JM, Aburto M, Moraza J, Arostegui I, Espana PP, Aizpiri S, Capelastegui A. The health, activity, dyspnea, obstruction, age, and hospitalization: prognostic score for stable COPD patients. Respir Med 2011; 105(11):1662-1670.
53. Roman A, Ussetti P, Sole A, Zurbano F, Borro JM, Vaquero JM, de PA, Morales P, Blanco M, Bravo C, Cifrian J, de la Torre M, et al. Guidelines for the selection of lung transplantation candidates. Arch Bronconeumol 2011; 47(6):303-309.
54. [Moving towards a new focus on COPD. The Spanish COPD Guidelines (GESEPOC)]. Arch Bronconeumol 2011; 47(8):379-381.
55. Bosse Y. Updates on the COPD gene list. Int J Chron Obstruct Pulmon Dis 2012; 7:607-631.
56. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182(5):598-604.
57. Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Pinera P, Simon A, Lopez-Campos JL, Soriano JB, et al. [Spanish COPD Guidelines (Ges EPOC): Pharmacological treatment of stable COPD]. Aten Primaria 2012; 44(7):425-437.
58. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008; 336(7650):924-926.
59. Koblizek V, Chlumsky J, Zindr V, Neumannova K, Zatloukal J, Zak J, Sedlak V, Kocianova J, Zatloukal J, Hejduk K, Pracharova S. Chronic Obstructive Pulmonary Disease: Offi cial diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157(2):189-201.
60. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identifi cation, defi nition and implications for guidelines. Arch Bronconeumol 2012; 48(3):86-98.
61. Soler-Cataluna JJ, Cosio B, Izquierdo JL, Lopez-Campos JL, Marin JM, Aguero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, Gonzalez MC, Miravitlles M, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012; 48(9):331-337.
62. Barnes PJ. Mechanisms in COPD: diff erences from asthma. Chest 2000; 117(2 Suppl):10S-14S.
63. Anthonisen NR. The British hypothesis revisited. Eur Respir J 2004; 23(5):657-658.
64. Postma DS, Boezen HM. Rationale for the Dutch hypothesis. Allergy and airway hyperresponsiveness as genetic factors and their interaction wiThenvironment in the development of asthma and COPD. Chest 2004; 126(2 Suppl):96S-104S.
65. Miravitlles M, Soriano JB, Ancochea J, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Garcia-Rio F. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med 2013; 107(7):1053-1060.
66. Nakawah MO, Hawkins C, Barbandi F. Asthma, Chronic Obstructive Pulmonary Disease (COPD), and the Overlap Syndrome. J Am Board Fam Med 2013; 26(4):470-477.
67. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol 2013; 131(3):627-634.
68. Miravitlles M, Soler-Cataluna JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41(6):1252-1256.
69. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31(4):742-750.
70. Vanfleteren LE, Kocks JW, Stone IS, Breyer-Kohansal R, Greulich T, Lacedonia D, Buhl R, Fabbri LM, Pavord ID, Barnes N, Wouters EF, Agusti A. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms Th orax 2014 Jan; 69(1):72-79.